WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)

The WTO Agreement on Trade‑Related Aspects of Intellectual Property Rights (TRIPS) is the single, binding multilateral treaty that sets the floor for intellectual‑property (IP) protection worldwide. Adopted at the Marrakesh Ministerial Conference on 15 April 1994 and effective from 1 January 1995, it links IP standards directly to the global trading system, making compliance a condition for WTO membership. By codifying minimum rights for patents, trademarks, copyrights, geographical indications and trade secrets, TRIPS created a uniform baseline that reshapes how nations balance innovators’ incentives with public‑interest goals such as access to medicines and cultural diffusion. ## Origins / Historical Background The TRIPS text appears as Annex 1C of the Marrakesh Agreement, the founding charter of the World Trade Organization. Its negotiation was the culmination of two decades of GATT‑era discussions on patents and copyrights, driven by the United States and the European Community’s demand for stronger IP safeguards in exchange for market‑opening concessions. When the agreement entered into force in 1995, it immediately imposed a 20‑year patent term (Article 33) and a life‑plus‑50‑year copyright term (Article 12) on all 164 WTO members as of 2024. The Doha Declaration on the TRIPS Agreement and Public Health, adopted in 2001, clarified that the treaty’s flexibilities—particularly compulsory licensing under Article 31—could be used to address public‑health emergencies. ## Key Provisions Article 27 obliges members to grant patents for any inventions, whether products or processes, in all fields of technology, subject only to limited exclusions such as diagnostic, therapeutic and surgical methods. Article 28 requires exclusive rights to be enforceable for the full 20‑year term, while Article 31 delineates the conditions under which a government may issue a compulsory licence, including the requirement of prior negotiation and adequate remuneration. Article 39 protects undisclosed information and trade secrets, mandating that measures against unfair competition be “effective” and “non‑discriminatory.” The treaty also sets out detailed standards for trademark registration (Article 15), geographical indications (Article 22), and the protection of layout‑designs of integrated circuits (Article 35). ## How It Works / Mechanism Each WTO member incorporates TRIPS into domestic law, but the agreement leaves room for “national treatment” and “most‑favoured‑nation” principles to shape implementation. Enforcement mechanisms operate through the WTO’s dispute‑settlement system: a complaining party may request consultations, and if unresolved, a panel and appellate review can impose retaliatory trade sanctions. Notable cases include US – Section 110(5) of the Patent Act (2003), which affirmed the right of a WTO member to limit patent enforcement for public‑policy reasons, and Canada – Patent Protection (2006), which clarified the scope of compulsory licensing for pharmaceuticals. The Doha Declaration’s “Paragraph 6” solution, operationalised by the 2003 Waiver Decision, permits countries with insufficient manufacturing capacity to import generic medicines produced under compulsory licences elsewhere. ## India’s Journey India entered the WTO in 1995 with a patent regime that recognised only process patents for pharmaceuticals. To meet TRIPS, the Parliament passed the Patents (Amendment) Act 2002, introducing product patents for drugs and chemicals, and the Patents (Amendment) Act 2005, which fully aligned Indian law with Articles 27 and 28. The 2007 Natco vs Bayer compulsory‑licence case was the first Indian use of Article 31, allowing a generic producer to manufacture a patented anticancer drug at a reduced price. Subsequent amendments in 2016 added a five‑year data‑exclusivity period for clinical trial information, reflecting pressure from developed‑country partners to tighten IP protection beyond the TRIPS floor. ## Current Status / Implementation As of 2024, all WTO members have enacted legislation that meets the TRIPS minimums, yet the depth of protection varies widely. The United States‑Mexico‑Canada Agreement (USMCA) and the EU‑India Free Trade Agreement negotiate “TRIPS‑plus” clauses that extend patent terms, introduce secondary patents, and tighten enforcement, sparking debate over their compatibility with development goals. At the 13th WTO Ministerial Conference in Abu Dhabi (2023), members discussed digital trade and the need to modernise IP rules for artificial‑intelligence‑generated works, but no amendment to the core text was adopted. Meanwhile, the World Health Organization continues to monitor the impact of compulsory licences on vaccine access, especially in the wake of the COVID‑19 pandemic. ## Significance TRIPS is the legal cornerstone that ties intellectual‑property rights to the global trading architecture, influencing everything from pharmaceutical pricing to the